GCP
VRTX icon

Garda Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Garda Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,700
Closed -$2.28M – 698
2025
Q1 		$2.28M Buy
+4,700
New +$2.19M 0.06% 317
2023
Q1 		– Sell
-16,500
Closed -$4.76M – 468
2022
Q4 		$4.76M Buy
+16,500
New +$5.03M 0.26% 115

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Garda Capital Partners's VRTX Position: Q1 2023 in Review

Garda Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 2,724 shares — an estimated $787K sold.

Garda Capital Partners first reported a position in VRTX in Q4 2022 and held it in 1 quarter. The position peaked at $787K in Q4 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

  • Garda Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Garda Capital Partners sold 2,724 Vertex Pharmaceuticals shares in Q1 2023, an estimated $787K.
  • Garda Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Garda Capital Partners's Vertex Pharmaceuticals position peaked at $787K in Q4 2022.
  • 1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Garda Capital Partners's 13F filing for Q1 2023, filed 10 May 2023.